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“Perhaps, as biologists, we may all agree on one aspect of nature, namely, its 
exceeding variety. Even a parasite may choose the course of manifest destiny 
and find aggressiveness more attractive and more valuable than an existence 
of peace and symbiosis.”  























Staphylococcus aureus (S. aureus) ist ein sehr vielfältiges, opportunistisches Humanpathogen. Neben der asymptomatischen Kolonisierung von Menschen kann es eine Vielzahl von Infektionen auslösen, die in ihrer Schwere variieren. Durch die Untersuchung von möglichen Verbindungen zwischen bestimmten Pathologien und bakteriellen Phänotypen sollten allgemeine und spezielle Infektionsmuster identifiziert werden. Dafür wurde eine Stammkollektion, basierend auf vier 








1. Introduction  




Figure 1 Morphology of S. aureus. A S. aureus forms yellow colonies with visible haemolytic clearance 
(strain dependent) on Columbia blood agar plate. B The scanning electron microscopy picture shows the 
clustering of S. aureus in grape-like structures. (Photo Credit: Janice Carr, Content Providers: CDC/ Matthew 




1.1 An inconspicuous neighbour – S. aureus as commensal The interaction between S. aureus and humans is very diverse. The bacterium is colonising 25-30% of all humans [11, 12] persistently without being eradicated by the host. Although the anterior nares are the most common site of colonisation [13], S. aureus can be isolated from throat, perineum, intestine, chest / abdomen, and axillae (s. Figure 2) which can be the exclusive colonisation location [14-16]. The decolonisation of S. aureus from the nose causes the vanishing from all other spots of colonisation which highlights the role of the nose as primary niche for staphylococcal colonisation [17, 18]. If expectant mothers are colonised with S. aureus, they will probably transmit their bacterial strain on their infant during or after birth [19-21]. Later in life, the main transmission route is from hand to hand or from surfaces to hand [22]. The habit of nose picking  promotes the transfer of staphylococci from hand to nose  thus encouraging colonisation [23]. If the S. aureus carrier is a heavy disperser and suffers from an infection of the upper airways, even an airborne transmission is possible [22, 24], however negligible, compared to the fact that most of those bacteria are transferred via direct contact [25].  Traditionally, three different types of time-defined carriage are differentiated: persistent, intermittent, and non-carriage [14]. The minority of people is permanently colonised with a single 




expressed adhesins (reviewed in [43]); it was shown that this bacterium survives intracellularly in the nasal epidermis of the anterior nares [44].  Regarding the immunological status, intermittent and non-carriers are much more alike than persistent S. aureus carriers as excellently reviewed by Mulcahy and McLoughlin [45]. Persistent carriers exhibit elevated levels of antibodies against superantigens of their very own strain [46]. At the same time, non-carriers and intermittent carriers show similar eradication mechanisms [13]. The well-established mutual adaptation of host and coloniser is corroborated by the re-selection of previous persistent S. aureus strain when the host is inoculated with a mixture of different strains [13]. Moreover, the mortality of infections caused by colonising staphylococci is lower than infections of non-colonising strains [11]. Based on the host immune system and response, several genetic variations were shown to be predisposing for colonisation [47-51]. Nevertheless, staphylococcal colonisation poses an elevated risk for invasive and life-threatening infections [11, 52, 53] and therefore tries to be eradicated. The first choice for S. aureus nasal de-colonisation is mupirocin [54], which is applied on the nasal mucosa topically [55]. The protein synthase inhibitor [56] induces an effective staphylococcal clearance for a few weeks. However, a re-colonisation was observed within a remarkably high proportion of people [57, 58]. Surprisingly, more than a third of the people were re-colonised with the same strain which was identified in the first place [59]. The low effectivity of several antibiotics, including mupirocin, against intracellular staphylococci could explain the poor outcome of long-term de-colonisation [60]. 





Figure 2 Diversity of staphylococcal colonisation niches and pathogenic interactions. * S. aureus is the 
main causative pathogen for the mentioned infection. References of indicated data are listed in Table S 1.  The knowledge about the mechanism of transition from healthy to pathogenic lifestyle in S. aureus is very poor. Nevertheless, a high age, diabetes mellitus, obesity, and vascular diseases are known predisposing factors on the host side [68]. Jenkins et al. simulated the actual process of transition by a three-phase cotton rat infection model [69]. It could be shown that the adhesins sdrC and 




However, the development of an infection is equally determined by host and pathogen. With the help of mathematical modelling, a double-switch motif was identified for 
Streptococcus pneumoniae, an opportunistic pathogen which can cause invasive lung infections [70]. The discovered motif includes the “R-switch” which represents the activation of toll-like receptors (TLRs) by the bacteria. The “S-switch” is the growth of transmigrated bacteria in the blood stream over a certain threshold. The combination of the state of those switches resulted in different pathologic and non-pathologic situations. The investigation of the existence of comparable central motifs in S. aureus should be investigated when appropriate data are available to train the model. It is likely that TLRs play a similar important role in infections with S. aureus as naturally occurring SNPs in the genes which code for TLRs and have been shown to change the susceptibility for infections with the named pathogen [71]. Furthermore, it is known that host “danger signals” (especially febrile temperature), which are triggered by a viral lung infection, promote the staphylococcal dispersal from colonisation sites in the nose to future infection sites in the lung [72]. The reduction of microflora diversity was shown to be beneficial for S. aureus overgrowth [73, 74] and therefore facilitate the transition to a more pathogenic bacterial lifestyle.  
1.2.1 The course of an invasive infection Even though the transition to the pathogenic lifestyle occurs relatively rarely, the absolute numbers for staphylococcal infections are high due to the ubiquitous presence in and on humans. An infection is defined as invasive when bacteria are isolated from naturally sterile body sites or fluid, like blood, cerebrospinal fluid, or joint fluid [75, 76]. Staphylococci can access these locations by direct introduction into deeper structures in context of an operation or insertion of foreign devices in the human body. It is also possible that staphylococci spread from primary infection foci to other body sites via the blood stream. S. aureus’ extensive arsenal of adhesins and virulence factors enables the bacterial survival in the blood stream by ensuring nutrient supply and fighting and evading the human immune system.  
1.3 “Go with the flow” – bacteraemia  




Moreover, S. aureus expresses the two siderophores staphyloferrin A and B which are competing with host iron complexing proteins transferrin and lactoferrin [78].  




advantage is on the bacterial side [103]. The solid clot of staphylococci interwoven with host fibrin creates on one hand a shelter from antibiotics [104, 105], and on the other hand, an aggregate which is too big to be swallowed by phagocytes [106]. Moreover, the “activation” of prothrombin by staphylococci is not based on proteolytic cleavage, which restricts the enzymatic activity on fibrinogen. Therefore, the physiological thrombin-mediated activation of proinflammatory signals and antibacterial agents, like bradykinin, is prevented [97].  On the other side, S. aureus is armed with many leukotoxins which provoke the generation of proinflammatory signals by active destruction of immune cells. The toxins Panton-Valentin leukocidin (PVL) and leukocidin AB/GH (LukAB/GH) can lyse white blood cells by creating pores in their outer membrane [107]. The same mechanism is found for leukocidin ED (LukED) and γ-toxin (HlgACB) [108-111].  There are indications that erythrocytes play a special role for the bacterial clearance in the blood flow [112, 113]. The researchers propose, that due to the high velocity, leukocytes are unable to phagocytose and pathogens can only be bound and destroyed by red blood cells [114].  
 




1.3.3 Adhesion to vascular endothelium  As S. aureus is facing the constant threat of a potentially deadly environment in the vasculature, strategies to leave the blood stream evolved in this pathogen. The retention time of staphylococci in the blood stream is very short as they are not detected in the blood 24 h post infection (p.i.) [115, 116]. The first step of the escape is the adherence to the endothelial tissue by single bacteria or agglutinated bacteria-fibrin clots [115]. This process is mediated by  several adhesins which are categorised by their linkage to the bacterial surface into microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) and secretable expanded repertoire adhesive molecules (SERAMs) [117]. In this context the most prominent representatives of the first adhesin family are the fibronectin-binding proteins A and B (FnBPA/B) which bind fibronectin on the surface of endothelial cells [115, 118]. The role of FnBPs is especially delicate as they trigger the bacterial uptake into host cells by bridging between fibronectin and integrin [119, 120]. This could represent a transcytotic way of leaving the bloodstream. The extracellular adherence protein (Eap) from the SERAM family can bind the endothelial cell adhesion molecule (ICAM-1) and can create an attachment by re-binding to the bacterium [121]. The previously described vWbp can bind to its eponymous von Willebrand factor which in turn binds to the endothelium [99]. There are also empiric evidence for the influence of the non-proteinaceous adhesin lipoteichoic acid (LTA) and wall teichoic acid (WTA) on the attachment to endothelium [122, 123].  




exposed [131]. In contrast to that, the formation of transient macroapertures represents a less damaging way of translocation. These tunnels stretch from the luminal to the basal site of the cell and are induced by the manipulation of the host actin cytoskeleton by bacterial epidermal cell differentiation inhibitors (EDINs) [132, 133].  
1.4 Sepsis The described battle between host and pathogen does not occur without major side effects for the infected person. In the worst case, the staphylococcal bacteraemia develops into sepsis which is defined presently as “life-threatening organ dysfunction caused by a dysregulated host response to infection” [134]. With 35 million yearly cases of sepsis worldwide and estimated 5.3 million deaths, S. aureus is the second leading pathogen causing this life threatening syndrome [8, 135-137]. As a result of the high incidence with its concurrent severity and expensive treatment costs [138], fast and exact diagnosis and treatment of S. aureus sepsis is strongly required.  
1.4.1 Sepsis diagnosis The fast, correct diagnosis of sepsis and the causing pathogen is of immense importance. It is suggested to save a blood sample before the onset of antimicrobial therapy in order to use the sample for the identification of circulating pathogens [139]. However, the timespan until reliable identification of the causing pathogen is 6 h to 5 d [140], highlighting the conflict between the need for correct information and the obligation of a fast therapy start. The gold standard for identification of pathogens in the blood is still blood culture with subsequent resistance testing. Indeed, there are several promising nucleic acid amplification technologies which unfortunately are limited regarding the range of detected pathogens, resistance spectrum, required amount of blood or requirement of elaborated sample preparation and handling [141].  




equipped with toxins that specifically harm leukocytes (PVL, LukAB/GH, LukED and Hlg). The destruction of white blood cells and host tissue generates damage-associated molecular patterns (DAMPs) which act as a second trigger for the progression of sepsis [142]. By causing an unphysiological, necrotic cell death, formerly intracellular compounds leak out and are recognised by the immune system as danger signal [142].  In sepsis, the overall failure of homeostasis is regarded as equally important as the immunological derailment [149]. Even though S. aureus-evolved strategies inhibit physiological coagulation in connection with the generation of unphysiological staphylothrombin, natural blood clotting is not prevented. As PAMPs are activating inflammatory mediators, the expression of tissue factor (TF) on primarily monocytes is promoted, too [150, 151]. In turn, TF is mainly responsible for massive thrombin generation in sepsis, leading to  coagulopathy [150]. The generated platelet-fibrin clots block the blood flow and increase the risk of bleeding as they consume excessive amounts of anticoagulant factors at the site of coagulation [152, 153]. The pathogen-induced NETs act as additional coagulation activators [154, 155]. As the coagulation system and the complement system are interconnected, coagulation activates the complement system. Therefore S. aureus attempts to prevent opsonisation via secretion of SCIN [156]. Together the TF-mediated coagulation, dysfunction of anticoagulation, and activation of complement, form a deadly triad which is known as disseminated vascular coagulopathy (DIC) [151]. The occurrence of DIC is linked to a poor prognosis [157]. The smallest blood vessels, known as the microvascular system, directly provide the tissue. In these vessels, the bacterial disturbance has the highest impact. In these structures the blood flow is slower than it is in larger vessels, which facilitates the bacterial adhesion to the endothelium [158, 159]. Moreover, the generation of thrombi leads to a total blockage of these vessels and subsequent undersupply of associated tissue. Thrombus formation acts together with other factors, like metabolic disentailments of the mesenchymal tissue, which causes organ damage and finally failure [158]. In addition to the induced coagulopathy, the bacterial expression of toxins for blood stream escape and the generally inflamed endothelium contributes to the increased endothelial permeability and resulting undersupply of tissue [160-164]. 




risk that accompanies the manipulation of them. This contradiction has led to the failure of more than 100 clinical studies on sepsis treatment [167].  The treatment of sepsis usually starts with antimicrobial therapy. Therefore, it is important that the therapy starts quickly (within 1h after diagnosis) with an antibiotic agent inside the bacterial susceptibility range. As described above, the diagnosis of the sepsis causing pathogen requires more than the requested 60 min to date. For this reason, a broad spectrum antibiotic is administered initially and replaced by a more specific antibiotic as fast  as possible [168]. In case of an S. aureus-induced sepsis, β-lactam antibiotics should be chosen for methicillin-susceptible 
S. aureus (MSSA) [169]. For MRSA no uniform recommendation  exists so far [169]. Furthermore, intravenous fluid should be administered to counteract tissue hypoperfusion. As coagulopathy is a fatal characteristic of sepsis, several therapeutic approaches tackle that symptom. The amount of physiological anti-coagulants  reduces in sepsis which is the reason anti-coagulants are administered [170]. However, if anti-coagulants are given in the later stages of sepsis, it is rather detrimental, as it can increase the risk of internal bleeding [151, 171]. Other therapy approaches that directly interfere with the human immune system by removing inflammatory mediators or addition of immune stimulators do not contribute to an improvement for all sepsis patients [172]. This finding indicates that the therapy must be adapted to the immune status of the patient, the stage of the infection, and the pathogen. Altogether, these challenges highlight the necessity of theranostics and personalised therapy [172]. One approach in that direction could be the division of patients into four different endotypes depending on representative markers [173]. As the development and manifestation of sepsis are very diverse, an individual assessment of the holistic clinical picture is of outstanding importance. Moreover, it was shown that the consultation of infectious disease experts for therapy advise, drastically lowers the mortality [169].  
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Figure 4 Development of osteomyelitis. A An abscess develops between the vascularised periosteum and 
the hard bone (cortex). B The enlargement of the abscess causes the lift of the periosteum, which results in 
the blockage of blood supply to the hard bone. C The undersupplied regions of the bone become necrotic, 
together with the abscess, the sequestrum is formed. If the periosteum is massively elevated, new bone 
formation occurs (involucrum) around the abscess region creating an encasing shell. Ultimately a sinus tract 
can spread from the abscess and devitalised structures, through soft tissue and skin. Illustration based on  
Kavanagh et al. [174] and  McNally &  Nagarajah [186].  The infection can develop from an initially easier treatable acute infection to a  hard-to-cure chronic infection [178, 187]. Therefore, the time frame for the diagnosis should be as small as possible in favour of the therapeutic success. All bones in the human body can be infected with 
S. aureus where the spine is usually accessed via the bloodstream [188, 189].  
1.5.1 Osteomyelitis diagnosis Many of the initial symptoms of spondylodiscitis (spine infections) and osteomyelitis are rather unspecific and multiform. Therefore, the diagnosis needs to include the various aspects of these infectious diseases in order to create a significant picture. Osteomyelitis can be diagnosed with the help of a score established by Schmidt et al. [190]. The score includes data on the anamnesis, clinical parameters with special emphasis on inflammatory markers, imaging diagnostics, microbiology, and histology. The diagnostic procedure for spondylodiscitis is in principle similar [191]. 








The presence of S. aureus in the usually sterile bone triggers an immunological reaction of osteoblasts. The bacterial PAMPs activate PRRs extracellularly (mostly  toll-like receptors TLRs, TNF-α receptor 1) and intracellularly nucleotide-binding oligomerization domain (NOD) and NOD-like receptor [220]. As a reaction upon PRR stimulation, the cells secrete chemokines (e.g. regulated on activation, normal T cell expressed and secreted = RANTES) that attract osteal macrophages and neutrophils [220]. Additionally, the attraction of Th1 lymphocytes as part of the adaptive immunity was observed [221]. The summoned macrophages are supposedly the main producer of the pro-inflammatory mediators IL1, IL-6, and TNF-α [220]. Exactly those three cytokines are known for their promoting effect on osteoclast function and differentiation resulting in bone resorption [222]. The inflammatory response in implant infections is even more pronounced as the implant is recognised as foreign material by the immune system. The following extensive immunological reaction is conversely beneficial for the pathogen as the abiding release of ROS induces a metabolic absorption of the neutrophils [223-225].  
 




Recurrent infections are a major complication in osteomyelitis as up to 40% of the patients are affected. Those relapses can ultimately lead to the exigency of limp amputation [174].  
1.6 Intracellular persistence  As highlighted before, S. aureus’ ability to persist inside different cell types poses a major threat for human health [238]. Staphylococci developed several mechanisms to deal with the imprisonment in phagosomes of professional and non-professional cells.  Compared with professional phagocytes, some non-professional phagocytes develop extenuated endosomes which are characterised by a low pH and antibacterial activity [239, 240]. If S.  aureus-containing phagosomes mature unaffectedly or if the maturation is detained, it seems to be dependent on host cell type  and / or staphylococcal strain [240]. Indeed, S. aureus was shown to be able to inhibit the fusion of phagosome and lysosome and therefore prevents its lysosomal degradation [241]. However, if phagosomal acidification is successful, S. aureus can be able to resist in this kind of environment or de-acidify it [240, 242].  Another coping strategy is based on the escape from host cell phagosomes. The phagosomal escape is mainly mediated through the expression of PSMs, especially PSMα [243, 244]. The PSM-induced pore formation in the endosomal membrane acquires additional factors (e.g. LukAB) to be effective [245]. Like many other virulence factors, psm expression is under the control of the 
agr regulon, which is why knock out of agr result in disabled phagosomal escape [245].  









1.7 Tailor-made changes? - of ecology, evolution and virulence The high expression of a variety of virulence factors in the bloodstream and the dynamic formation of “silent” SCVs emphasises two antagonistic survival strategies within the same bacterium. The development of this pattern can be enlightened with regard to evolutionary processes.   Evolutionary success is defined by means of fitness which is in turn described as the successful production of offspring. According to this definition, species with a high fitness will increase over time in number and outgrow competitors with a lower fitness [256]. It is generally accepted that virulence is an unavoidable symptom of host exploitation in favour of the pathogen survival, reproduction, and transmission to a new host [257]. The existence of competing bacterial species will select for the higher virulence, resulting in disadvantages in the transmission and promoting negative selection [257]. Virulence is defined as the decrease of host fitness which can be translated in a medical microbiological context to “harm or morbidity to the host” [258]. The definition of a “pathogen” is more complex than it initially seems as it is not just a disease-causing agent. As Méthot and Alizon highlighted in their configurational model, a pathogen can only be identified and defined in relation to its host and environment [259]. This construct implies that commensalism and parasitism are constantly merging and the development of a disease is equally shaped by host and bacterium [259]. The fact that severe diseases like sepsis are mainly caused by the immunopathology of the host itself emphasises this last assumption [260]. 









Figure 5 Ecological and evolutionary dynamics that influence the development of virulence factors. A 
General model. NA and NV represent bacterial densities in the asymptomatic (A) and virulence sites (V), 
respectively. Arrows represent demographic processes of growth (g, r) and transmission (colonisation c, 
export e). B Model for pre-adaptation. If properties in the asymptomatic and virulence sites are positively 
correlated, pre-adaptation can occur. Positive selection in either environment optimises the population for 
survival in the other environment. C Model of environmental trade-off. If the benign and the virulent 
environment are negatively correlated, adaptation to one environment is attended by a disadvantage in 
the other environment (trade off). Red arrows: positive selective impact, blue arrows: negative selective 




1.7.2 Quorum sensing induced regulation of cytotoxicity in S. aureus The agr quorum sensing system is central to the adaptive regulation of cytotoxicity in S. aureus. The agr locus codes for two divergent transcripts [272]. In the upstream direction RNAII includes 
agrB, agrD, agrC, agrA. In the opposite direction the transcript RNAIII acts as small regulatory RNA and contains the gene for haemolysin delta at the same time. The RNAII-associated promoter P2 is permanently active on a low level. The transcribed Agr proteins have very distinct functions in the generation, perception, and reaction onto quorum sensing signals. AgrD represents a precursor of the autoinducing peptide (AIP). This precursor is transported extracellularly and maturated by the agrB-coded multifunctional transmembrane protein.  
 If staphylococci accumulate locally and the level of AIP rises upon a certain threshold, the membrane histidine kinase ArgC is activated by autophosphorylation. This in turn results in phosphorylation of intracellular AgrA, the central response regulator of this system. The activated 
 
 
Figure 6 Quorum sensing induced regulation of cytotoxicity in S. aureus. High bacterial densities lead to 
accumulation of extracellular AIP, which activates AgrC. The cytosolic kinase of activated AgrC 
phosphorylates AgrA that acts as a transcription factor for RNAII and RNAIII. The RNAII sequence includes 
genes for AgrB, AgrD, AgrC, and AgrA. The transcribed RNAIII acts mainly as small regulatory RNA which 
promotes the transcription of toxins and inhibits the transcription of genes for adhesion and biofilm 













2. Material and methods 
2.1 Material and instruments 
Table 1 Instruments 
Instrument Characteristic Company (town, country) 
Bacteria incubator Heraeus B12 Heraeus (Hanau, Germany) 
Cameras Canon PowerShot G16, Canon EOS 1100D 
Canon (Tokyo, Japan) 
Cell counter TC 20™ Bio-Rad (Hercules, CA, U.S.A.) 
Cell culture freezing container Mr. Frosty™ 
Thermo Fisher Scientific™ 
(Waltham, MA, USA) 
Cell incubator LAB.INC.A/J T/C CO2 W/DCN 
Thermo Fisher Scientific™ 
(Waltham, MA, USA) 
Centrifuges 5810 R, 5417 R Eppendorf (Hamburg, Germany) 
Clean bench Biowizard golden line Kojair (Vilppula, Finnland) 
Colony counter colonyQuant 
Schuett Biotec (Göttingen, 
Germany) 
Electrophoresis power supply PowerPac 200 Power Supply Bio-Rad (Hercules, CA, U.S.A.) 
Electroporation device Gene Pulser II + Controller Bio-Rad (Hercules, CA, U.S.A.) 
enzyme-linked immunosorbent 
assay (ELISA) reader Infinite 200Pro 
Tecan (Männedorf, Switzerland) 
FACS BD Accuri C6+ 
BD Biosciences (Erembodegem, 
Belgium) 
Gel documentation station 
Molecular Imager ® GelDoc XR 
System Bio-Rad (Hercules, CA, U.S.A.) 
Homogeniser FastPrep-24 MP biomedicals (Shandong, China) 
Inverse light microscope Nikon TMS Nikon (Tokyo, Japan) 
Magnetic stirrer RH basic IKA (Staufen, Germany) 
Photometer  Ultrospec 2000 UV/VIS  
Pharmacia Biotech (Uppsala, 
Schweden)  
Pipetting robot QIAgility Qiagen (Hilden, Germany) 
Quantitative Real time PCR 
cycler Rotor-Gene Q 
Qiagen (Hilden, Germany) 
Shaking incubator TH 30 
Edmund Bühler GmbH (Tübingen, 
Germany) 




Spektrophotometer NanoDrop ND-1000 Spectrophotometer 
Peqlab, Erlangen, Germany 
Thermocycler  Biometra® TRIO- Thermoblock 
TM + TRIO Heated Lid 
Biometra biomedizinische Analytik 
GmbH (Göttingen, Germany) 
Tissue homogeniser Polytron® 2500 Kinematica (Luzern, Switzerland) 
Vacuum pump BVC professional Vaccubrand (Wertheim, Germany) 
Vortex mixer WIZARD IR Infrared Vortex Mixer VELP Scientifica (Usmate Italy) 
Water bath GFL 1003 GFL (Großburgwedel, Germany) 
 
Table 2 Chemicals and Kits 
Chemical  company 
Agarose Serva (Heidelberg, Germany) 
cDNA synthesis QuantiNova Reverse 
transcription Kit 
Qiagen (Hilden, Germany) 
Chloroform Carl Roth (Karlsruhe, Germany) 
Dimethyl sulfoxide Sigma-Aldrich (St. Louis, MO, U.S.A) 
Ethanol VWR International (Radnor, PA, U.S.A) 
Ethidiumbromide Carl Roth (Karlsruhe, Germany) 
Isopropanol Carl Roth (Karlsruhe, Germany) 
Nuclease-free water Thermo Fisher Scientific™ (Waltham, MA, USA) 
Plasmid Midi Kit Qiagen (Hilden, Germany) 
Propidium iodide Sigma-Aldrich (St. Louis, MO, U.S.A) 
QIAquick PCR Purification Kit Qiagen (Hilden, Germany) 
Sodium bicarbonate (NaHCO3) Carl Roth (Karlsruhe, Germany) 
Sodium carbonate (Na2CO3) Sigma-Aldrich (St. Louis, MO, U.S.A) 
TRIzol™ Thermo Fisher Scientific™ (Waltham, MA, USA) 
 
Table 3 Media (cell culture and bacteria culture) 
Medium company 
Accutase Solution PromoCell (Heidelberg, Germany) 
brain heart infusion (BHI) Oxoid (Hampshire, U.K.) 
Collagenase  Sigma-Aldrich (St. Louis, MO, U.S.A) 




Endothelial Cell Growth Medium with 
supplement 
PromoCell (Heidelberg, Germany) 
FBS superior Biochrom (Berlin, Germany) 
Fibronectin Roche (Basel, Switzerland) 
Ham's F12 DMEM/F12, no phenol red Thermo Fisher Scientific™ (Waltham, MA, USA) 
HAT Supplement (50X) Thermo Fisher Scientific™ (Waltham, MA, USA) 
Human serum albumin (HSA) Albunorm Octapharma (Lachen, Switzerland)  
Hydroxyethyl-piperazineethane-sulfonic 
acid buffer (HEPES-buffer) 
Biochrom (Berlin, Germany) 
L-Ascorbic acid 2-phosphate 
sesquimagnesium salt hydrate 
Sigma-Aldrich (St. Louis, MO, U.S.A) 
Medium 199 Lonza (Basel, Switzerland) 
Mueller Hinton Oxoid (Hampshire, U.K.) 
Minimum essential medium α (α-MEM) 
with nucleotides 
Biochrom (Berlin, Germany) 
β-Glycerophosphate disodium salt 
hydrate, BioUltra 
Sigma-Aldrich (St. Louis, MO, U.S.A) 
 
Table 4 Antibiotics 
Product Company  
Geneticin® Selective Antibiotic (G418 
Sulfate) 
Thermo Fisher Scientific™ (Waltham, MA, USA) 
Gentamycin Ratiopharm (Ulm, Germany) 
Lysostaphin Ambi Products LLC (Lawrence, NY, U.S.A.) 
Penicillin / Streptomycin Biochrom (Berlin, Germany) 
 









145 nt [247] Reverse  5’-GGCAATGAGTCTGTGAGATTT-3’ 
gyrB 
Forward 5’-AATTGAAGCAGGCTATGTGT-3’ 
138 nt [247] Reverse  5’-ATAGACCATTTTGGTGTTGG-3’ 
hla 
Forward 5’-CAACTGATAAAAAAGTAGGCTGGAAAGTGAT-
3’ 201 nt [276]  
Reverse  5’-CTGGTGAAAACCCTGAAGATAATAGAG-3’ 
psmα 
Forward 5’-GCCATTCACATGGAATTCGT-3’ 
151 nt This institute Reverse  5’-CAATAGCCATCGTTTTGTCCT-3’ 
rnaIII 
Forward 5’-TTCACTGTGTCGATAATCCA-3’ 
70 nt [251]  Reverse  5’-TGATTTCAATGGCACAAGAT-3’ 




Reverse  5'-TTCTTGTAGTGGGTTTGCGTAG-3' 
 
Table 6 Consumables 
Product Company 
12-well plates Greiner Bio-One (Kremsmünster, Austria) 
96-well F-bottom plates Greiner Bio-One (Kremsmünster, Austria) 
96-well V bottom plates Greiner Bio-One (Kremsmünster, Austria) 
Cell culture flasks (25cm2, 75cm2, 175cm2) Greiner Bio-One (Kremsmünster, Austria) 
Cell scraper Sarstedt (Nümbrecht, Germany) 
Cuvettes Sarstedt (Nümbrecht, Germany) 
Pipette tips Nerbe plus (Winsen, Germany) 
Polystyrene round bottom tubes Sarstedt (Nümbrecht, Germany) 
 
Table 7 Software 
Software  Company 
BD Accuri™ C6 Software BD Biosciences (Erembodegem, Belgium) 
GraphPad Prism 6 GraphPad Software (San Diego, CA, U.S.A.) 
MS Office Microsoft Corporation (Redmond, USA) 
PCR software, Rotor-Gene Q Qiagen (Hilden, Germany) 







2.2.1 Study group and bacterial isolates The bacterial isolates were obtained from a strain collection at the Jena University Hospital as well as from the microbiological routine diagnostic department at the Institute of Medical Microbiology. The sampling of strains and the documentation of selected patient data was approved by the local ethics committee of the University Hospital Jena (registration no.: 4874-07/16). The corresponding patients and healthy people resided in Thuringia and the adjacent federal states (Saxony-Anhalt, Bavaria, Hesse). No informed consent was needed as all testing was performed with clinical strains and not with patient samples. The isolates were grouped depending on the donor into the categories: sepsis, haematogenous osteomyelitis, prosthesis infection, and nasal isolates from healthy people. 
2.2.2 Clinical definitions Sepsis was defined according to the definition by the Third Sepsis Consensus Conference in the year 2016 as “[a] life-threatening organ dysfunction due to a dysregulated host response to infection.” This is evaluated by the Sepsis-related Organ Failure Assessment (SOFA) score or the simplified form, the quick SOFA (qSOFA) [277]. The qSOFA criteria are fast respiratory rate, altered mental state, and lowered blood pressure. If two of the three criteria are fulfilled, the chances for a severe organ dysfunction, and therefore a sepsis, are high. The qSOFA was used in this work to identify patients for the sepsis group. Moreover, there are two groups with bone infections; whereas, the group of haematogenous osteomyelitis is defined by an additional 
S. aureus-positive blood culture. In turn, a history of bone operations with an implementation of a prosthesis and a negative blood culture define the prosthesis infection group.  Group assignment was kindly done by Dr. Stefanie Deinhardt-Emmer.  




variants. The differences between the isolate groups and the CCs were analysed by two-sided Fisher’s exact test with IBM SPSS Statistics 24.  
2.2.4 Growth curve and generation time  For growth curves, S. aureus strains were grown at 37 °C with shaking (160 rpm) overnight in 5 ml of BHI. On the following day, 200 µl of BHI in a 96-well F-bottom plate were inoculated with each strain to obtain an optical density (OD) 0.05 (578 nm). The growth of each strain was monitored spectrophotometrically every 15 min over 16 h with a plate reader. The growth rate (μ, growth speed) and the generation time (g) for each strain used in this study were calculated according the standard formula by Madigan et al. [278].   
2.2.5 Haemolysis assay To assess the ability of the strains to secrete haemolytic toxins, a haemolysis assay was conducted. Therefore, defibrinated sheep blood was washed with Dulbecco's phosphate-buffered saline (DPBS) (500 xg 10 min) several times until the supernatant was clear from free haemoglobin. Then, a 1.7% solution was prepared in DPBS with the pelleted erythrocytes. A previously described protocol was modified in the following way: 5 ml of a BHI medium in a conical flask were inoculated with a single colony of S. aureus patient isolates and incubated at 37 °C with an agitation of 160 rpm for 15 h. On the next day, the overnight culture was centrifuged at 12,000 rpm at 4 °C for 5 min to obtain whole culture supernatant. Then, 100 µl of the supernatant were mixed with the same amount of the previously prepared erythrocyte solution in a V-Bottom plate. The mixture was incubated at 37 °C, 5% CO2 for 30 min. To separate intact erythrocytes from the supernatant with the released haemoglobin, the plate was centrifuged at 1000 rpm and 4 °C for 5 min. The supernatant was subsequently transferred to a new F-bottom plate. The free haemoglobin was quantified by absorbance measurement at 570 nm, whereas supernatant of the high haemolytic S. aureus strain Wood46 was used as positive control.  
2.2.6 Cell culture  
2.2.6.1 Isolation of primary cells (pHOBs, HUVEC) and cultivation of osteoblast cell 




For the isolation of human umbilical vein endothelial cells (HUVECs) umbilical cords were received from the Sophien/Hufeland-Klinikum, Weimar. The isolation was conducted under sterile conditions. At the beginning, the outside of the umbilical cords was manually cleaned with prewarmed DPBS. Then, the ends of the cord were cut with a scissor, and stainless steel luer adaptors were inserted into the larger vein. The luer adaptors were fixed with cable ties. A syringe with pre-warmed DPBS was connected to one luer adaptor and the DPBS was pushed through the vein until the emergent liquid was clear. Afterwards a syringe with collagenase (0.2% wt/vol in DPBS) was plugged to the other luer and the enzyme solution was pushed into the vein. The filled umbilical cord was incubated at 37 °C for 30 min. Then both syringes were removed, and the vein slowly flushed with pre-warmed Medium 199. During this process, the cord was manually massaged to detach as much cells as possible. All of the liquid was collected in a 30 ml falcon tube. The obtained cell suspension was centrifuged 5 min 1.000 xg and the supernatant was removed subsequently. The remaining cell pellet was resuspended in HUVEC full medium (Endothelial Cell Growth Medium with supplement + 10% FBS + 100 U/ml, 100 µg/ml penicillin / streptomycin) and seeded into one well of a 6-well plate which was incubated at 37 °C. After the cells reached confluence, they were detached with 500 µl accutase-solution and seeded into a fibronectin coated, 75 cm2 cell culture bottle. For coating 1 ml of pure fibronectin (1 mg/ml in ddH2O) was pipetted and suspended in a 75 cm2 cell culture bottle.  The osteoblast cell line hFOB1.19 was grown at 34 °C where these cells exhibit a short doubling time and the phenotype of an immature osteoblast. The basic medium Ham's F12 DMEM/F12 contained additionally 10% FBS and 0.3 mg/ml G418. G418 is an aminoglycoside antibiotic which is used to select for a desired, genetically modified cell type. As it is toxic for wild type eukaryotic cells and bacteria, this additive was omitted for infection experiments.  




Detached cells were resuspended in an adequate amount of full medium and seeded into a cell culture plate or flask. When cells needed to be frozen for long time storage, cells were washed and detached as described for subcultivation. The detached cells were counted with a cell counter. After a 5 min centrifugation at 500 xg, the cell pellet was resuspended in a respective amount of freezing medium (basic medium + 8% DMSO) to adjust the cell concentration to 0.5 – 1x106. The cell suspension was aliquoted into cryogenic vials which were transferred to a pre-cooled freezing container. This container prevented the formation of big ice crystals by slow cooling. The filled container was stored for 15 min at 4 °C and for 24 h at -80 °C before the vials were moved to the liquid nitrogen tank.  








Figure 7 Exemplary representation of FACS gates for determination of invasiveness in osteoblasts 
(hFOBs). A Gates were adjusted to uninfected host cells to correct for autofluorescence of measured 
osteoblasts. B The high infecting strain S. aureus CowanI was used as positive control.  
  
2.2.8 Cell death assay 










Figure 8 Exemplary representation of FACS gates for determination of cytotoxicity on osteoblasts 
(hFOBs). A Gates were adjusted to uninfected, unstained host cells to correct for autofluorescence of 
measured osteoblasts. B An experiment was only conducted if the cell death of uninfected cells was lower 
than 10%. C The high cytotoxic strain S. aureus 6850 was used as positive control.  
  




types of cells to a significantly lower extent, whereas the highest values were measured in the experiment with pHOBs as host cells. For the cytotoxicity assay the general mortality of the uninfected host cells was decisive for the number of dead cells after infection. The osteoblast cell line (hFOB 1.19) showed the lowest values and the primary endothelial cells (HUVECs) were most likely to die with or without infection. However, when high and low cytotoxic bacteria were compared, the pattern always remained the same. All in all, the specific type of host cells played only a minor role when different strains were compared as the relation between high and low value strains persisted independently of the host cell background. For the sake of time and effort, the osteoblast cell line hFOB 1.19 was used for the screening of the clinical isolates and the persistence assay.  
A B 
  
Figure 9 Comparison of osteoblast cell line (hFOB 1.19) with primary human osteoblasts (pHOB) and primary 
human umbilical vein endothelial cells (HUVECs) for A invasion and B cytotoxicity assay. A The high invasive 
strain invaded all types of cells to a similar degree. The low invasive strain (S. carnosus TM300) showed the 
highest invasion when they were co-cultivated with pHOBs. B The high cytotoxic strain (6850) destroyed the 
most cells; whereas, the low cytotoxic strain showed cytotoxicity levels which were slightly higher than the 
uninfected control. In general, the number of dead cells was the lowest when the osteoblast cell line was used. 
Significance was tested with paired, two-sided t-test. The differences between the cell line hFOB 1.19 and the 
primary cells were not statistically significant.   




The plates were incubated for 72 h and every 24 h colony forming units (CFUs) and SCVs were counted with a colony counter (Schuett colonyQuant, Göttingen, Germany). SCVs were defined by a diameter of <0.8 mm.  
2.2.10 Measurement of the released chemokine RANTES Osteoblasts (hFOB1.19) were seeded into 12-well plates and infected with staphylococci in a similar order as described for the long-term persistence model. The supernatant was removed 24 h and 48 h after the infection and stored at -80 °C. To determine the exact number of host cells, osteoblasts were detached, as described for the invasion assay, and quantified flow-cytometrically. The obtained supernatants and sera from mice were analysed with RANTES human Instant ELISA™ and RANTES Mouse Instant ELISA™ respectively (ThermoFisher Scientific).   




(gDNA) digest and the complementary DNA (cDNA) synthesis were done with the QuantiNova Reverse transcription Kit according to manufactures instruction. The resulting cDNA solution was used for quantitative real-time PCR with QuantiNova SYBR Green PCR Kit in a Rotor-Gene Q thermocycler. The reaction mixtures were incubated for 15 min at 95 °C followed by 40 cycles of 15 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. The primers are listed in Table 5. The fold change was calculated by the Pfaffl equation [283]. The housekeeping gene gyrB was used as a reference gene.   





3.1 S. aureus patient isolates of different origin showed just slight genotypic 
differences 
3.1.1 Clinical characteristics of patients differ in a group-specific manner In order to compare strains from different pathologic backgrounds, a collection of 47 bacterial isolates was established. The group of nasal colonisation from healthy people and the group of prosthesis infection included 12 strains. Ten strains were collected from sepsis patients and 13 strains isolated from patients suffering from haematogenous osteomyelitis. Selected medical characteristics are listed in Table 8. The age was comparable between the three different patient groups; whereas, people from the group of nasal colonisation were marginally younger. The percentage of men was raised in the group of prosthesis infections compared to the other groups which showed a more balanced sex ratio. The highest mortality was found for the haematogenous osteomyelitis patients where more than one third died from the infection. In the sepsis group every fifth case turned out to be fatal. In contrast to that, none of the patients from the prosthesis infection group died from S. aureus infection.  








Total number 12 12 13 10  
median age [years] 
49.08 66 75.23 62.7 
<0.001 (range 40-64) (range 33-85) (range 47-96) 
(range 53-
78) 
Male 6 (50,0%) b 9 (75.0%) 8 (61.5%) 5 (50,0%) 0.738 
Case fatality - 0 5 (38.5%) 2 (20.0%) 0.042 
Underlying condition 
Immunosuppression - 2 (16.7%) 3 (23.1%) 3 (30.0%) 0.759 
Diabetes mellitus - 2 (16.7%) 5 (38.5%) 7 (70.0%) 0.043 
Malignant disease - 0 2 (15.4%) 2 (20.0%) 0.841 
Indwelling devices - 7 (58.3%) 2 (15.4%) 1 (10.0%) 0.025 
Renal disease - 5 (41.7%) 12 (92.3%) 7 (70.0%) 0.024 
Cardiovascular disease - 9 (75.0%) 8 (61.5%) 9 (90.0%) 0.345 
Liver disease - 3 (25.0%) 1 (7.7%) 4 (40.0%) 0.160 
Mean number of 
comorbidities / patients - 2.42 2.58 3.3 
0.1365 
Origin of infection / primary focus 
Unknown - 0 3 (23.0%) 0 0.096 
Bone - 12 (100%) 7 (53.8%) 0 ≤0.001 
Wound / skin - 0 1 (7.7%) 2 (20.0%) 0.268 
Intravenous catheter - 0 2 (15.4%) 0 0.318 
Lung - 0 0 6 (60.0%) ≤0.001 




 Regarding the underlying conditions of the patients, diabetes mellitus was found more often in the severe diseases of haematogenous osteomyelitis and sepsis; while more patients with prosthesis infections were dependent on indwelling devices at the same time. When both bone infection groups were compared, almost all patients in the haematogenous group were suffering from an impaired renal function. In contrast, in the other group, only half of the patients showed the same condition. The bacterial infection mainly originated from the bone in both bone-infection groups. In contrast, the lung was the predominant source of infection in the sepsis patients. Interestingly, the median length of hospital stay was the highest for the prosthesis infection group and the lowest for the sepsis group, whereas the group of haematogenous osteomyelitis stood in between.   
3.1.2 Affiliation of clinical isolates to population groups  The affiliation of the S. aureus isolates to CCs were determined by genotyping (s. Table 9). In total, 13 different clonal complexes were observed among all tested Staphylococci. The distribution of 
Hospital stays during last 3 years (in relation to infection) 
None - 3 (25%) 10 (76.9%) 9 (90.0%)  
1 - 0 2 (15.4%) 0  
≥2 - 9 (75%) 1 (7.7%) 1 (10.0%)  
Median length of hospital 
stay [days] - 
60 (range 





a binary variables were tested with Fisher’s exact test, non-binary parametric variables were tested with one-
way  analysis of variance (ANOVA), whereas non-parametric binary variables were tested with Kruskal-Wallis 
test 
b one sample could not be assigned to sex 
c no data available for one isolate from the group of prosthesis infection  









osteomyelitis Sepsis pa 
(n = 12) (n = 12) (n = 13) (n = 10) 
CC1 0 0 7,7% (1) 10,0% (1) 0,578 
CC5 16,6% (2) 25% (3) 0 10,0% (1) 0,271 
CC6 8,3% (1) 8,3% (1) 7,7% (1) 0 1,000 
CC7 0 33,3% (4) 0 0 0,007 
CC8 0 16,6% (2) 15,4% (2) 10,0% (1) 0,620 
CC15 8,3% (1) 0 15,4% (2) 10,0% (1) 0,717 
CC22 0 0 30,8% (4) 30,0% (3) 0,019 
CC25 8,3% (1) 0 7,7% (1) 0 1,000 
CC30 16,6% (2) 8,3% (1) 0 0 0,382 
CC45 25% (3) 0 7,7% (1) 30,0% (3) 0,116 
CC101 0 0 7,7% (1) 0 1,000 
CC121 0 8,3% (1) 0 0 0,723 




clonal complexes in the defined groups was very diverse as every group contained at least six different CCs.  None of the CCs from this sample was found in all isolate groups; CC5, CC6, CC8, CC15 and CC45 were found in at least three of the groups. The CC7 was found in a high percentage and exclusively in isolates from prosthesis infections. Furthermore, in the two isolates groups which originated from blood infections, haematogenous osteomyelitis and sepsis showed similarities in the distribution of CCs. CC22 had the highest frequency in both groups and was not found in any of the other groups.    
3.2 Prevalence of selected virulence factors among S. aureus isolates The complete microarray hybridisation data are provided as a supplementary file (s. Table S 2). The data are displayed in three different ways to facilitate the evaluation. The combination of genes and isolate groups displayed in Table 10 and Table 11 contains the information about the frequency of genes within the clonal complexes. For the sake of clarity, rare CCs of this study (CC1; CC25; CC101; CC121, CC398) are summarised in one group in Table 11.   
3.2.1 Regulation In all the groups the main agr was agrI, with a frequency of 60% -70%. The gene agrII was found in all the groups, too; while 15% - 25% of all strains harboured that gene. Only a small proportion allotted to agrIII and agrIV. On a clonal level it was observed that CC5 was associated with agrII and CC30 with agrIII. All residual CCs were majoritarian associated with agrI.  




Table 10 Frequencies of selected genes in the defined isolate groups. 








agrI Accessory gene regulator allele I 58.3% (7) 66.7% (8) 69.2% (9) 70.0% (7) 0,950 
agrII Accessory gene regulator allele II 25.0% (3) 25.0% (3) 15.4% (2) 20.0% (2) 0.928 
agrIII Accessory gene regulator allele III 16.7% (2) 8.3% (1) 7.7% (1) 10.0% (1) 0.927 
agrIV Accessory gene regulator allele IV 0 0 7.7% (1) 0 1.000 
Resistance 
bla β-lactamase 58.3% (7) 58.3% (7) 46.2% (6) 90.0% (9) 0.184 
ermA Erythromycin / clindamycin resistance gene A 0 16.7% (2) 0 20.0% (2) 0.171 
ermB Erythromycin / clindamycin resistance gene B 0 0 0 0 - 
ermc Erythromycin / clindamycin resistance gene C 0 8.3% (1) 0 0 0.723 
fosB Metallothiol transferase 58.3% (7) 66.7% (8) 53.8% (7) 30.0% (3) 0.419 
mecA Alternate penicillin binding protein 2, defining MRSA 0 16.7% (2) 7.7% (1) 10.0% (1) 0.612 
sdrM  Putative Transport-/ efflux protein 100% (12) 100% (12) 69.2% (9) 70.0% (7) 0.029 
tetK Tetracycline resistance gene K 0 0 7.7% (1) 10.0% (1) 0.578 
tetM Tetracycline resistance gene M 0 8.3% (1) 0 0 0.723 
vanA Vancomycin resistance gene 0 0 0 0 - 
Enterotoxins 
sea Staphylococcal enterotoxin A 16.7% (2) 16.7% (2) 15.4% (2) 0 0.597 
seb Staphylococcal enterotoxin B 8.3% (1) 0 15.4% (2) 0 0.603 
sec, sel Staphylococcal enterotoxin C+L 25.0% (3) 0 15.4% (2) 10.0% (1) 0.332 
sed, sej, ser Staphylococcal enterotoxin D+J+R 0 25.0% (3) 7.7% (1) 20.0% (2) 0.244 
see Staphylococcal enterotoxin E 0 0 0 0 - 
egc-cluster Staphylococcal enterotoxin G+I+M+N+O+U 66.7% (8) 33.3% (4) 53.8% (7) 70.0% (7) 0.289 
seh Staphylococcal enterotoxin H 8.3% (1) 0 7.7% (1) 10.0% (1) 0.885 
sek, seq Staphylococcal enterotoxin K+Q 0 8.3% (1) 7.7% (1) 0 1.000 
tst1 Toxic shock syndrome toxin (TSST)-1 16.7% (2) 0 0 0 0.164 





hla α-toxin 100% (12) 100% (12) 100% (13) 100% (10) - 
hlb β-toxin 75.0% (9) 100% (12) 84.6% (11) 80.0% (8) 0.381 
hld δ-toxin 100% (12) 100% (12) 100% (13) 100% (10) - 
Leucocidins 
lukF, hlgA γ-toxin 100% (12) 100% (12) 100% (13) 100% (10) - 
lukF-PV Panton-Valentin-leucotoxin 8.3% (1) 0 0 0 0.723 
lukD, lukE Leucocidin D, E component 41.7% (5) c 91.7% (11) c 61.5% (8) 40.0% (4) 0.034 
Exfoliative toxins 
etA Exfoliative toxin A 8.3% (1) 0 0 0 0.723 
etB Exfoliative toxin B 0 0 0 0 - 
etD Exfoliative toxin D 8.3% (1) 0 7.7% (1) 0 1.000 
Enzymes 
aur Aureolysin 100% (12) 100% (12) 100% (13) 100% (10) - 
chp Chemotaxis inhibitory protein (CHIP) 66.7% (8) 25.0% (3) 61.5% (8) 80.0% (8) 0.056 
splA, splB Serine protease A, B 41.7% (5)d 91.7% (11)d 61.5% (8) 40.0% (4)d 0.034 
splE Serine protease E 41.7% (5) 66,7% (8)e 46.2% (6) 10% (1)e 0.065 
sspA, sspB Glutamyl endopeptidase 100% (12) 100% (12) 100% (13) 100% (10) - 
sak Staphylokinase 66.7% (8)f 100% (12)f 84.6% (11) 80.0% (8) 0.173 
scn Staphylococcal complement inhibitor 91.7% (11) 100% (12) 100% (13) 100% (10) 0.723 
Exopolysaccharides 
cap5 Capsular polysaccharide 5 41.7% (5) 41.7% (5) 46.2% (6) 50.0% (5)  1.000 
cap8 Capsular polysaccharide 8 58.3% (7) 58.3% (7) 53.8% (7) 50.0% (5) 1.000 
icaA, D, C Polysaccharide intracellular adhesin 100% (12) 100% (12) 100% (13) 100% (10) - 
Adhesins 
bbp Bone sialoprotein-binding protein 91.7% (11) 91.7% (11) 100% (13) 100% (10) 0.711 
clfA, clfB Clumping factor A and B 100% (12) 100% (12) 100% (13) 100% (10) - 
cna Collagen binding adhesin 58.3% (7) 25.0% (3) 61.5% (8) 70.0% (7) 0.151 
ebh Cell wall associated fibronectin-binding protein 100% (12) 100% (12) 69.2% (9) 70.0% (7) 0.019 
ebps Cell surface elastin-binding protein 100% (12) 100% (12) 100% (13) 100% (10) - 
eno Enolase 100% (12) 100% (12) 100% (13) 100% (10) - 
fib Fibrinogen-binding protein 100% (12) 100% (12) 100% (13) 100% (10) - 




fnbB Fibronectin-binding protein B 83.3% (10) 83.3% (10) 69.2% (9) 100% (10) 0.315 
map Major histocompatibility complex class II analog protein 100% (12) 91.7% (11) 100% (13) 100% (10) 0.723 
sasG S. aureus surface protein G 33.3% (4) 58.3% (7) 69.2% (9) 70.0% (7) 0.259 
sdrC Serine-aspartate repeat protein C 100% (12) 100% (12) 100% (13) 100% (10) - 
sdrD Serine-aspartate repeat protein D 91.7% (11) 91.7% (11) 92.3% (12) 100% (10) 1.000 




Epidermal cell differentiation 
inhibitor A+C 0 0 0 0 - 
edinB Epidermal cell differentiation inhibitor B 8.3% (1) 0 7.7% (1) 0 1.000 
setC* Staphylococcal exotoxin-like protein 66.7% (8)
g 91.7% (11) 100% (13)g 100% (10) 0.079 
ssl6 Staphylococcal superantigen-like protein 6 8.3% (1)
h 58.3% (7)h 38.5% (5) 30.0% (3) 0.077 
ssl8 Staphylococcal superantigen-like protein 8 41.7% (5)
i 91.7% (11)i 61.5% (8) 40.0% (4)i 0.034 
ssl11 Staphylococcal superantigen-like protein 11 75.0% (9) 100% (12)
j 53.8% (7)j 40.0% (4)j 0.007 
a p values were calculated with Fisher’s exact test; b significant difference between nasal colonisation and prosthesis 
infection (p=0.037), and between prosthesis infection and haematogenous OM (p=0.015); c significant difference between 
nasal colonisation and prosthesis infection (p=0.027) and prosthesis infection and sepsis (p=0.02); d significant difference 
between nasal colonisation and prosthesis infection (p=0.027) and prosthesis infection and sepsis (p=0.02); e significant 
difference between prosthesis infection and sepsis (p=0.011); f significant difference between nasal colonisation and 
prosthesis infection (p=0.047); g significant difference between prosthesis infection and haematogenous OM (p=0.039); 
h significant difference between nasal colonisation and prosthesis infection (p=0.027); i significant difference between 
nasal colonisation and prosthesis infection (p=0.027) and prosthesis infection and sepsis (p=0.02); j significant difference 
between prosthesis infection and haematogenous OM (p=0.015) and prosthesis infection and sepsis (p=0.03) 
 
 




3.2.4 Leucocidins & Exfoliative toxins The γ-toxin coding gene was present in all the strains. The lukD and lukE genes were found significantly more often in the prosthesis infections group and were never found in combination with CC30, CC45, and CC398. The only isolate with a PVL gene originated from a nasal colonisation. Moreover, two of the three exfoliative toxin genes found were present in the same patient group of nasal colonisation.   
3.2.5 Enzymes The genes for aureolysin, glutamyl endopeptidase, staphylokinase, and staphylococcal complement inhibitor were detected in every strain or in almost every strain. The gene chp showed a very high frequency in the sepsis group. In contrast, it showed a very low frequency in the prosthesis group. The genes of the serine proteases A, B and E were most prevalent in the prosthesis group and less prevalent in the group of nasal and sepsis origin. The presence of those serine protease genes was significantly different between the clonal complexes. In detail none or only one isolate of CC30 and CC45 harboured the gene for serine protease A, B; whereas, the majority of CC was endowed with these genes. It was remarkable that all isolates of CC6, CC7 and CC30 were equipped with the serine protease E gene.   
3.2.6 Exopolysaccharides & adhesins All strains were equipped with either the cap5 or cap8 capsule coding gene. No group-specific distribution of the cap genes was evident. In all strains genes of the polysaccharide intracellular adhesin could be detected.  All isolates or almost all isolates were endowed with the adhesin genes bbp, clfA, ebps, eno, fib, 
fnbA. map, sdrC, sdrD, and vwb. An origin-specific distribution was observed for the gene ebh with a low frequency in groups of haematogenous osteomyelitis and sepsis. The CC30 stood out on the clonal level as this complex did not contain any genes for fibronectin-binding protein B, S. aureus surface protein G, and a low frequency of major histocompatibility complex class II analog protein gene.  








Table 11 Distribution of selected genes according to main clonal complexes. 
Gene Product CC5 CC6 CC7 CC8 CC15 CC22 CC30 CC45 Rare CCsa pb 
 Regulation 6 3 4 5 4 7 3 7 8  
agrI Accessory gene regulator allele I 16.7% (1) 66.7% (2) 100% (4) 80% (4) 75% (3) 57.1% (4) 0 85.7% (6) 87.5% (7) 0.017 
agrII Accessory gene regulator allele II 83.3% (5) 33.3% (1) 0 0 25% (1) 28.6% (2) 0 14.3% (1) 0 0.008 
agrIII Accessory gene regulator allele III 0 0 0 0 0 14.3% (1) 100% (3) 0 12.5% (1) 0.002 
agrIV Accessory gene regulator allele IV 0 0 0 20% (1) 0 0 0 0 0 0.404 
 Resistance           
bla β-lactamase 50.0% (3) 66.7% (2) 50.0% (2) 80.0% (4) 50.0% (2) 57.1% (4) 66.7% (2) 71.4% (5) 62.5% (5) 0.989 
ermA Erythromycin / clindamycin resistance gene A 16.7% (1) 0 0 0 25.0% (1) 0 0 14.3% (1) 12.5% (1) 0.923 
ermB Erythromycin / clindamycin resistance gene B 0 0 0 0 0 0 0 0 0 - 
ermc Erythromycin / clindamycin resistance gene C 0 0 0 20.0% (1) 0 0 0 0 0 0.404 
fosB Metallothiol transferase 83.3% (5) 100% (3) 0 60.0% (3) 75.0% (3) 57.1% (4) 100% (3) 14.3% (1) 37.5% (3) 0.017 
mecA Alternate penicillin binding protein 2, defining MRSA 16.7% (1) 0 0 0 0 14.3% (1) 0 14.3% (1) 12.5% (1) 1.000 
sdrM Transport-/ efflux protein 100% (6) 100% (3) 100% (4) 80.0% (4) 100% (4) 71.4% (5) 100% (3) 57.1% (4) 87.5% (7) 0.510 
tetK Tetracycline resistance gene K 0 0 0 0 0 28.6% (2) 0 0 0 0.322 
tetM Tetracycline resistance gene M 0 0 0 0 0 0 0 0 12.5% (1) 1.000 




 Enterotoxins           
sea Staphylococcal enterotoxin A 0 66.7% (2) 0 0 0 14.3% (1) 33.3% (1) 0 25.0% (2) 0.085 
seb Staphylococcal enterotoxin B 0 0 0 20.0% (1) 0 0 0 0 25.0% (2) 0.511 




D+J+R 16.7% (1) 0 0 40.0% (2) 25.0% (1) 14.3% (1) 0 14.3% (1) 0 0.646 




G+I+M+N+O+U 100% (6) 0 0 60.0% (3) 25.0% (1) 28.6% (2) 100% (3) 100% (7) 50.0% (4) 0.000 
seh Staphylococcal enterotoxin H 0 0 0 0 0 14.3% (1) 33.3% (1) 0 12.5% (1) 0.699 
sek, seq Staphylococcal enterotoxin K+Q 0 0 0 0 0 0 0 0 25.0% (2) 0.540 
tst1 Toxic shock syndrome toxin (TSST)-1 0 0 0 0 0 0 66.7% (2) 0 0 0.006 
entP Enterotoxin P 16.7% (1) 0 100% (4) 0 0 0 0 14.3% (1) 0 0.000 
 Haemolysins           
hla α-toxin 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
hlb β-toxin 83.3% (5) 66.7% (2) 100% (4) 80.0% (4) 100% (4) 100% (7) 100% (3) 85.7% (6) 100% (8) 0.871 
hld δ-toxin 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
 Leucocidins           
lukF, 
hlgA γ-toxin 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
lukF-PV Panton-Valentin-leucotoxin 0 0 0 0 0 0 0 0 12.5% (1) 1.000 
lukD, 




 Exfoliative toxins CC5 CC6 CC7 CC8 CC15 CC22 CC30 CC45  pa 
etA Exfoliative toxin A 0 0 0 0 0 0 0 14.3% (1) 0 0.830 
etB Exfoliative toxin B 0 0 0 0 0 0 0 0 0 - 
etD Exfoliative toxin D 0 0 0 0 0 0 0 0 25.0% (2) 0.540 
 Enzymes           
aur Aureolysin 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
chp Chemotaxis inhibitory protein (CHIP) 50.0% (3) 33.3% (1) 0 40.0% (2) 50.0% (2) 57.1% (4) 100% (3) 85.7% (6) 75.0% (6) 0.131 
splA, 
splB Serine protease A, B 83.3% (5) 100% (3) 100% (4) 60.0% (3) 75.0% (3) 71.4% (5) 0 14.3% (1) 50.0% (4) 0.022 
splE Serine protease E 0 100% (3) 100% (4) 40.0% (2) 50.0% (2) 42.9% (3) 100% (3) 0 37.5% (3) 0.001 
sspA, 
sspB Glutamyl endopeptidase 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
sak Staphylokinase 100% (6) 66.7% (2) 100% (4) 100% (5) 75.0% (3) 57.1% (4) 100% (3) 85.7% (6) 75.0% (6) 0.478 
scn Staphylococcal complement inhibitor 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 85.7% (6) 100% (8) 0.830 
 Exopolysaccharides           
cap5 Capsular polysaccharide 5 83.3% (5) 0 0 60.0% (3) 25.0% (1) 42.9% (3) 0 57.1% (4) 62.5% (5) 0.081 




adhesin 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
 Adhesins           





clfB Clumping factors A and B 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
cna Collagen binding adhesin 16.7% (1) 66.7% (2) 0 60.0% (3) 25.0% (1) 57.1% (4) 66.7% (2) 85.7% (6) 75.0% (6) 0.069 
ebh Cell wall associated fibronectin-binding protein 100% (6) 100% (3) 100% (4) 80.0% (4) 100% (4) 71.4% (5) 100% (3) 57.1% (4) 87.5% (7) 0.510 
ebps Cell surface elastin-binding protein 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
eno Enolase 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
fib Fibrinogen-binding protein 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
fnbA Fibronectin-binding protein A 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
fnbB Fibronectin-binding protein B 100% (6) 100% (3) 100% (4) 60.0% (3) 100% (4) 85.7% (6) 0 85.7% (6) 100% (8) 0.018 
map Major histocompatibility complex class II analog protein 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 66.7% (2) 100% (7) 100% (8) 0.128 
sasG S. aureus surface protein G 83.3% (5) 100% (3) 0 60.0% (3) 50.0% (2) 100% (7) 0 57.1% (4) 37.5% (3) 0.005 
sdrC Serine-aspartate repeat protein C 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
sdrD Serine-aspartate repeat protein D 100% (6) 100% (3) 100% (4) 100% (5) 75.0% (3) 85.7% (6) 66.7% (2) 100% (7) 100% (8) 0.256 
vwb Van Willebrand factor binding protein 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 100% (3) 100% (7) 100% (8) - 
 Miscellaneous CC5 CC6 CC7 CC8 CC15 CC22 CC30 CC45   
edinA, 
edinC 
Epidermal cell differentiation 
inhibitor A+C 0 0 0 0 0 0 0 0 0 - 
edinB Epidermal cell differentiation inhibitor B 0 0 0 0 0 0 0 0 25.0% (2) 0.540 
setC Staphylococcal exotoxin-like protein 100% (6) 100% (3) 100% (4) 100% (5) 100% (4) 100% (7) 0 71.4% (5) 100% (8) 0.000 




ssl8 Staphylococcal superantigen-like protein 8 83.3% (5) 100% (3) 100% (4) 60.0% (3) 75.0% (3) 71.4% (5) 0 14.3% (1) 50.0% (4) 0.022 
ssl11 Staphylococcal superantigen-like protein 11 83.3% (5) 100% (3) 100% (4) 60.0% (3) 75.0% (3) 71.4% (5) 100% (3) 14.3% (1) 62.5% (5) 0.072 
a CCs with fewer than three isolates (CC1, CC25, CC101, CC121, CC398) were summarised in one group  




3.3 Bacterial origin did not determine differences in cytotoxicity  To determine the influence of the described genotypic differences on the phenotype, additional functional assays were performed.  To exclude differences in growth behaviour as an influencing factor on other phenotypic traits, the bacterial growth was monitored (s. Figure 10). One strain stood out due to its slowed growth which was visible after overnight incubation on Columbia blood agar plates as well as in the respective growth curve. However, the vast majority of strains showed a normal, group-unrelated growth dynamic. 
A B 
  
Figure 10 Growth dynamic of S. aureus patient isolates. Clinical S. aureus isolates were monitored over 16 h 
by photometrical measurement of the optical density. A The increase of the optical density over time shows 
a homogenous growth for all strains except the strain Hawa51. B When strains were categorised by the 
infectious situation they were isolated from, no group specific difference could be detected. The differences 















Figure 11 Group affiliation was not associated with a specific phenotype or gene expression level of selected 
central virulence regulators. A The osteoblast cell line hFOB 1.19 was infected with FITC-stained S. aureus and the 
quantity of intracellular bacteria was determined by flow cytometry. B The approximate bacterial load of the 
osteoblast with the stained staphylococci was assessed by measurement of the mean fluorescence intensity of the 
invaded host cells. C The osteoblasts were infected with clinical S. aureus isolates and the rate of dead cells was 
quantified 24h p.i. flow cytometrically. D The haemolytic ability of the strains was assessed by the co-incubation of 
bacterial culture supernatants with sheep blood erythrocytes. Secreted haemolytic compounds in the supernatant 





3.4 Investigation of group-unrelated correlations As no group-specific pattern could be detected in the previously described experiments, the pairwise correlation of all data sets was calculated (s. Figure 12). The expression of all investigated genes was positively correlated, whereas the most significant correlations were found between agr and rnaIII (p<0.001, r= 0.55), rnaIII and psmα (p<0.001, r= 0.67), and psmα and hla (p<0.001, r= 0.58). The selected genes were key factors for the staphylococcal virulence and were therefore engaged in the same or overlapping processes. As these processes usually led to the death of the host cell, the detected positive correlation between cytotoxicity and hla (p=0.001, r=0.46), rnaIII (p<0.001, r= 0.53) and psmα (p<0.001, r= 0.61) was reasonable. The cytotoxic ability was additionally correlated with haemolysis (p=0.013, r=0.37), which indicates that both mechanisms were driven by shared actions. This was underlined by the positive correlation of haemolysis to the same genetic factors as seen for cytotoxicity (hla: p=0.008; r=0.38, 
rnaIII: p=0.001; r= 0.49, psmα: p<0.001, r= 0.52). Surprisingly, cytotoxicity and haemolysis showed a negative correlation to the invasiveness (p=0.026 r=-0.33) (p=0.004 r=-0.42) which suggested that these were opposing characteristics. It was observed that invasion and bacterial load were strongly correlated (p<0.001, r= 0.82) and shared the same pattern for correlation with the other factors (s. Table S 3). A correlation of the generation time with any of the other characteristics could not be confirmed (s. Table S 3).   
  
spectrophotometer at a wavelength of 570nm. E Gene expression of S. aureus clinical isolates. All isolates were 
cultivated in BHI for 4 h (agrA, rnaIII) and 6 h (psmα, hla), respectively. The RNA was isolated and reversely 
transcribed into complementary DNA (cDNA) in order to perform qPCR. The slow growing strain Hawa51 was not 
included in the graph for the gene expression data due to its changed growth dynamic. The bars and whiskers 
represent the means ±SD of at least three independent experiments in duplicate. The differences between the 






3.4.1 High bacterial cytotoxicity and low invasiveness are beneficial for 
persistence inside host cells  
S. aureus is able to hide from the immune system within cells of the host for longer times by downregulating the gene expression for general metabolism and toxins [248]. This persistence ability is an important virulence trait and was therefore assessed with a long-time persistence model (s. Figure 13). Special attention was paid to a possible association of virulence, namely high cytotoxicity and haemolysis, and persistence. For this reason, four high and three low cytotoxic strains were selected for infection of osteoblasts. The infected cells were lysed at previously 
 
 
Figure 12 Non-parametric correlation analysis of all measured parameters. The two-sided p-values are 
represented by a colour coding scheme (heat map) where the p-value decreases from light (high p-value, low 
significance) to dark blue (low p-value, high significance). Spearman’s rank correlation coefficient is displayed 
as numbers. Data for the strain Hawa51 (SCV phenotype) are excluded from correlation analysis. The full 















































Figure 13 Long-term persistence of low and high cytotoxic strains in osteoblasts. A Intracellular bacteria 
recovered from infected osteoblasts for four high cytotoxic strains (black lines) and three low cytotoxic strains 
(gray lines) as a function of time p.i.. B Intracellular bacteria recovered from infected osteoblasts with high 
and low cytotoxic strains at day 7 p.i.. C SCVs recovered at day 7 p.i.. D RANTES levels were measured in cell 
culture supernatant of infected osteoblasts after 24-h p.i. using ELISA test. All results represent the means of 
of at least three independent experiments ± SD. The difference between low and high cytotoxic strains was 




The secretion of CCL5 was reduced in a significant grade in the cells which were infected with low cytotoxic strains. In summary, the low cytotoxic strains persisted in higher numbers over the course of infection by transition of a higher percentage of bacteria to the SCV phenotype which caused a reduced host immunological reaction compared to high cytotoxic strains.   
3.4.2 Low cytotoxic strains persist in higher numbers in the murine sepsis model 









Figure 14 High-cytotoxic strain induced high inflammation and fast clearance by the host in the mouse 
sepsis model. C57/BL6 mice were infected with Chwa42 (low cytotoxic) or D2 (high cytotoxic) strains for 6 
weeks. A The relative weight of the mice decreased a few days after infection as a symptom of the 
development of sepsis. After survival of the septic condition, the weight constantly increased. B Survival 
curves of the infected mice with Chwa42 (n=8) and D2 (n=10). No differences were observed by a long-rank 
(Mantel Cox) test. C The bacterial loads within the hind limbs were analysed after 6 weeks p.i.. Bar and 
whiskers represent mean±SD. Statistical analysis was performed with an unpaired t-test comparing the 
bacterial load in hind limbs (*p =0.0021). D RANTES levels in serum were measured after 3 days p.i.. 
Statistical analysis was performed using the unpaired t-test comparing abundance of RANTES in the serum 
(*p  ≤= 0.0015). 

















strains are not fundamentally different from each other” [319] when it comes to causing a particular disease. The combination of both approaches results in a theory where the strains are as different as it is observed in the functional assays but due to the individual interplay with different hosts, they produce a uniform clinical picture. This theory includes two assumptions: first, that different strategies lead to the same result, and second, that the combination of host and pathogen is important. The dynamic concept, which forms the basis of the pathogen definition, harmonises with this idea [259].   The link between genetic constitution and the bacterial phenotype is gene expression. To elucidate the regulation of virulence, the expression of selected genes was examined. The amount of expressed quorum sensing accessory gene regulator (agr) and its effector molecule RNAIII per strain in dependence of the isolate group displayed a similar pattern as seen for the functional assays. The low expression of agr and even the complete dysfunction of the gene  were shown to be conducive for the development of infections, especially in the hospital setting [322]. Moreover, 









Figure 15 In the course of infection, low cytotoxic strains have an advantage over high cytotoxic strains due 
to their higher invasion, lower cytotoxicity, and better persistence inside the host cells. High and low 
cytotoxic strains represent two distinct infection strategies. High cytotoxic strains have a generally higher level 
of agr and rnaIII regulated toxin gene expression (e.g. hla and psmα). Induced by the damaging effects of the 
secreted toxins, the host cells release corresponding amounts of cytokines. Some cytokines can further 
increase the bacterial induced cell death. The combination of high levels of staphylococcal toxins and host 
cytokines lead to a pronounced reduction of intact host cells in infections with high cytotoxic strains. As host 
cells serve as sheltering compartment for long-time persistence, low cytotoxic S. aureus strains can persist in 
higher numbers while exhibiting the SCV phenotype more often. Measured by the recovery of living 
intracellular bacteria, “silent” infection with low cytotoxic strains is the more successful strategy in a mono-




It would be helpful to address this issue from an ecological aspect. When analysing the relation of 
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Table S 1 References for S. aureus colonisation rates at different parts of the human body 
Interaction / infection Reference 











Toxic shock syndrome [350] 
Osteomyelitis [178] 
Septic arthritis [351] 
Diabetic foot infections [352] 




Table S 2 Complete results of DNA -microarray.  A = ambiguous, N = negative, P = positive 
  Nasal colonisation Prosthesis infection Haematogenous osteomyelitis Sepsis 
     








































































































































































































































































































































































































































































































































































































































































































































































Domain 1 of 




e, locus 1 
gapA P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
katalase A katA P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 




nuc1 P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
staphylococcal 
protein A spa  P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
IgG-binding 








saeS P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 




agrI (total) N P P P P N P N N P N P N N P P P P N N P P P P P N P N P N P P P P P P N P P N P P P P N P N 
agrB-I N P P P P N P N N P N P N N P P P P N N P P P P P A P N P N P P P P P P N P P N P P P P N P N 
agrC-I N P P A P N P N N P N P N N P P P P N N P P P P P P P N P N P P P P P P N P P N P P P P N P N 




agrII (total) N N N N N P N P P N N N P N N N N N P P N N N N N N N P N P N N N N N N N N N P N N N N N N P 
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haemolysin 
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cassette 
chromosome 
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kdpC-SCC N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N P 
sensor kinase 



























ccrA-3 N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N 




merA N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 














N N N N N N N N N N N A N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 





ccrA-4 N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N P N N N N 
ccrB-4 N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N P N N P N 
SCCmec XI 
mecC N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
blaZ-SCCmec XI N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
beta-




























































vga N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 


































dfrA N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
fusidic acid 










mupR N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
tetrazyklin-
resistance tetK N N N N N N N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N P N N 
tetracycline-





cat  N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
cat (pC221) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
cat (pc223) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
cat (pMC524) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 








fexA N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
metallothiol 
transferase 
fosB P P P N N P N P P N P N P P P N P P P P N N N P N P P P N P P N N P N P N N N P N N N P N N P 












qacC  N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
qacC (cons) N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
qacC (equine) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
qacC (SA5) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
qacC (Ssap) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
qacC (ST94) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
Transport-





















(consensus) P N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
tst1 ("human" 
allele) 
P N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
tst1 ("bovine" 
allele) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 




entA (320E)  N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
enterotoxin A, 
allele from 
strain N315 = 
entero-toxin P 
entA (N315) / 
entP 
N N N N N N N N N N N N P N N P N N N N P P P N N N N N N N N N N N N N N N N N N N N N N N P 
enterotoxin B entB N N P N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N P N N N N N N N N N N 
enterotoxin C entC N N N P N N N N N P N P N N N N N N N N N N N N N N N N N N N P N N P N N N N N N N N N P N N 
enterotoxin D entD N N N N N N N N N N N N N N P N N P P N N N N N N N N N N N N N N P N N N N N N N N N P N N P 
enterotoxin E entE N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
enterotoxin G entG P N P P N P N N P N P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 
enterotoxin H entH N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N P N N 
enterotoxin I entI P N P P N P N N P P P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 
enterotoxin J entJ N N N N N N N N N N N N A N P N N P P N N N N N N N N N N N N N N P N N N N N N N N N P N N P 
enterotoxin K entK N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N P N N N N N N N N N N 
enterotoxin L entL N N N P N N N N N P N P A N N N N N N N N N N N N N N N N N N P N N P N N N N N N N N N P N N 
enterotoxin M entM P N P P N P N N P P P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 






P N P P N P N N P P P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 
enterotoxin O entO P N P P N P N N P P P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 
egc cluster egc (total) P N P P N P N N P P P P P P N N N N P P N N N N P P P N P N N P P N P N N P P N P P P N N P P 
enterotoxin Q entQ N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N P N N N N N N N N N N 
enterotoxin R entR N N N N N N N N N N N N N N P N N P P N N N N N N N N N N N N N N P N N N N N N N N N P N N P 
Enterotoxin U 





probe1 N N N N N N N N N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N 
entCM14 
probe2 










lukS P P P A P P P P P P P A P P P N P P P P A P P P P P P P N P P P P P P P P A A P P P P P P A P 
lukS 




























lukM N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
leukocidin D 
component lukD N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
leukocidin E 









lukY  N P P N P P P P P N N N P N P P P P P P P P P P P P P P P P P N P P P P P P N P N N P P P P P 
lukY 




hl P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
haemolysin 




hlIII (cons) P P P P P P P P P P P P P P P P P P P P P P P P N P P P N P P P N P N P P N P P P P N P P N P 
hlIII (other 
than RF122) P P P N P P P P P N P N P P P P P P P P P P P P N N P P N P P N N P N P P N N P N N N P P N P 
haemolysin 
beta 
hlb-probe 1 P P P N P P P N P N P N P P P P N P P P P P P P P P P N P N P N P P P P P P N N N P P P P P P 
hlb-probe 2 P P P N P P P N P N P N P P P P P P P P P P P P P P P N P N P N P P P P P P N N N P P P P P P 
hlb-probe 3 A P P N N P N P P N P N P P P P N P P P P P P P P P P N P P P N P P P P P P N P N N P P P P P 
un-truncated 
hlb N N N N N N N N N P N N N P N N N A N N N A N N N N N N N N N N N N N N N N N N N N N N N N N 
staphylo-
















etB N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
exfoliative 















edinC N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
ACME-locus ACME (total) N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 














arcD-SCC N N N N N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 







N P P N N P N P P N N N P N P P P P P P P P P N N P P P N P P N N P N P P N N P N N N P P N P 
aur (MRSA252) P N N P P N P N N P P P N P N N N N N N N N N P P N N N P N N P P N P N N P P N P P P N N P N 
serin- protease 
A splA N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
serin- protease 
B splB N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
serin- protease 
E splE P P P N N N N P N N P N N P P P P P N N P P P N N N P P N P P N N P N N P N N P N N N N N N N 
glutamylendop
eptidase sspA P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
staphopain B, 




sspP (cons) P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
sspP (other 
than ST93) 




setC N P P A P P P P P P N A P N P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
staphylococcal 
superantigen-
like protein 1 
set6-var1_11 N N N N P P P N P N N N P N P P N P P P P P P P N P N N N N N N N P N N N N N N N N N P N N P 
set6-var2_11 P N P P N N N P N P P P N P N N N N N N N N N N P N P N P P N P P N P P P P P A P P P N P P N 
set6-var1_12 P N N N P P P N P A P N P P N N N A P P N N N P P P N N P N A P P P P N N P A N A A P P N P P 
set6-var2_12    N N N N N N N N N N N N N N N P N N N N P P P N N N N N N N N N N N N P P N N N N N N N P N N 
set6-var4_11 P P P P P P P P P P P A P P P N P P P P N N N P N P P P N P P P N P N N N N P P P P N P N N P 
ssl01-RF122 N P N N N N N N N N N N N N N N P N N N N N N N N N N N N N P N N N N N N N N N N N N N N N N 
ssl01/set6 
(COL) N N N N N N N N N N N N N N P N N P N N N N N P N N N N N N N N N P N N N N N N N N N P N N N 
ssl01/set6 
(Mu50+N315) 




N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N P P N N N N N N N P N N 
ssl01/set6 
(MRSA252) P N N N N N N N N N P N N P N N N N N N N N N N P N N N P N N P P N P N N P N N N N P N N P N 
ssl01/set6 
(RF122) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
ssl01/set6 
(other alleles) 
N P P P N N N P N P N P N N N P P N N N P P P N N N P P N P P N N N N N N N P P P P N N N N N 
staphylococcal 
superantigen-
like protein 2 
ssl02/set7 N P P N N P A P P N N N P N P P P P P P P P P P A P P P A P P A P P A P P P N P N N A P P P P 
ssl02/set7 
(MRSA252) P N N P P A P N A P P P A P N N N N A A N A A N P N N N P N A P A A P N A A P N P P P A A A N 
staphylococcal 
superantigen-
like protein 3 
ssl03/set8_pro
be 1 
N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
ssl03/set8_pro




P N N N N N N N N N P N N P N N N N N N N N N N P N N N N N N N N N P N N N N N N N N N N N N 
staphylococcal 
superantigen-
like protein 4 




P N N P P N P N N P P P N P N N N N N N N N N N P N N N P N N P P N P N A P P N P P P N N P N 
staphylococcal 
superantigen-
like protein 5 
ssl05/set3_pro




N P A N N A N P A N N N A N A N P A N A N N N A N P P P N P A N N A N A A N N P N N N A A N N 
ssl05/set3_pro
be 2 (612) 
N A P N N P N A P N N N P N P P A P P P P P P P N A A A N A P N N P N P P N N A N N N P P N P 
ssl05/set3 
(MRSA252) P N N P P N P N N P P P N P N N N N N N N N N N P N N N P N N P P N P N N P P N P P P N N P N 
staphylococcal 
superantigen-
like protein 6 




N N N N N N N P N N N N N N P P N P N N P P P P N P N P N P N A N P N N P N N P N N N P P N N 
staphylococcal 
superantigen-
like protein 7 
ssl07/set1 N P P N A P A P P N N N P N P P P P P P P P P P A P P P N P P N A P A P P A N P N N A P P A P 
ssl07/set1 
(MRSA252) 
P N N N A A P A A N P N A P N A N N A A A A A A A A N N A A N A A N A A A A N A N N A N A A A 
ssl07/set1 
(AF188836) N N N P P A A N N P N P N N N N N N N A N A N N P N N N P N N P P N P N A P P N N N P N A P N 
staphylococcal 
superantigen-
like protein 8 
ssl08/set12_pr
obe 1 N P P N N P N A P N N N P N P P P P P P P P P P N P P N N A P N N P N P P N N P N N N P P N P 
ssl08/set12_pr
obe 2 N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
staphylococcal 
superantigen-
like protein 9 
ssl09/set5_pro
be 1 N P P N N P N P P N N N P N P P P P P P P P P P P P P P P P P N P P P P P P N P N N P P P P P 
ssl09/set5_pro
be 2 
N P P N N P N P P N N N P N P P P P P P P P P P P P P P P P P N P P P P P P N P N N P P P P P 
ssl09/set5 
(MRSA252) P N N P P N P N N P P P N P N N N N N N N N N N N N N N N N N P N N N N N N P N P P N N N N N 
staphylococcal 
superantigen-
like protein 10 
ssl10/set4 A A P A P P A P P P A A P A P P A P P P P P P P P P A A N A P P P P P P P N P A P P P P P N P 
ssl10 (RF122) N P A N N N N A N N N N N N N N P N N N N N N N N A P P N P A N N N N N N N N P N N N N N N N 
ssl10/set4 
(MRSA252) P N A P A A P N A A P P A P A A N A A A A A A A A N A N N N A A N A A A A N A N A A A A A N N 
staphylococcal 
superantigene-
like protein 11 
ssl11/set2 
(COL) N N N N N N N N N N N N N N P N N P N N N N N P N N N N N N N N N P N N N N N N N N N P N N N 
ssl11+set2(Mu
50+N315) N P N N N P N N P N N N P N N N P N P P N N N N N N N N N N P N N N N N N N N N N N N N N N P 
ssl11+set2(M











setB3 N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
setB3  
(MRSA252) P N N P P N P N N P P P N P N N N N N N N N N N N N N N N N N P N N N N N N P N P P N N N N N 
setB2 N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 
setB2  
(MRSA252) 
P N N N P N P N N N P P N P N N N N N N N N N N N N N N N N N P N N N N N N P N P P N N N N N 
setB1 P P P N P P P P P N P A P N P P P P P P P P P P N P P P N P P A N P N P P N N P N N N P P N P 





capH1 N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
O-antigen 





capK1 N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 





capH5 N N P N P P P N P N N N P N P N N P P P N N N N P N P N P N N N P P P N N P N N N N P P N P P 
O-antigen 





capK5 N N P N P P P N P N N N P N P N N P P P N N N N P N P N P N N N P P P N N P N N N N P P N P P 










capI8 P P N P N N N P N P P P N P N P P N N N P P P P N P N P N P P P N N N P P N P P P P N N P N N 
O-antigen 



























bbp P P P P P P P N P P P P P N P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
bbp (cons) P P P P P P P N P P P P P N P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
bbp 
(COL+MW2) N P P N A N A N N N N N N N P P P P N N P P P P N N P N N N P N N P N P P N N N N N N P P N N 
bbp 
(MRSA252) P N N N N N N N N N P N N N N A N N N N A A A N N P N N N N N N N N N A N N N N N N N N N N N 
bbp (Mu50) N N A N A P A N P N N N P N N N N A P P N N N A P N A P N P A A P A P N A N A P A A P A A N P 
bbp (RF122) N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N 
bbp (ST45) N N N P P N P N N P N P N N N N N N N N N N N N N N N N N N N P N N N N N N P N P P N N N N N 
clumping 
factor A 
clfA  P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
clfA (cons) P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
clfA 
(COL+RF122) A N N A P N P N N A A N N A P P N P N N P P P P N N N N N N N A N P N P N N A N A A N P N N N 
clfA 
(MRSA252) P N N N A N A N N N P N N P A A N A N N A A A A N N N N N N N N N A N A N N N N N N N A N N N 
clfA 
(Mu50+MW2) N P P P A P A P P P N P P N A A P A P P A A A A P P P P P P P P P A P A P P P P P P P A P P P 
clumping 
factor B 
clfB P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
clfB (cons) P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
clfB 
(COL+Mu50) 
N N N N N P N N P N N N P N P N N P P P N N N N N N N N N N N N N P N N N N N N N N N P N N P 
clfB (MW2) N N N P P N P P N P P P N N N N N N N N N N N N N N N P N P N P N N N N P N P P P P N N P N N 














ebpS P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
ebpS_probe 
612 P P P N N P N P P N P N P P P P A P P P P P P P P N P A A P P N P P P P P P N P N N P P P P P 
ebpS_probe 
614 P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
ebpS (01-1111) N N N P P N P N N P N P N N N N N N N N N N N N N P N N N N N P N N N N N N P N P P N N N N N 
ebpS (COL) N N P N P N P P N N N N N N P P N P N N P P P P P N P P P P N N P P P N N P N P N N P P N P N 





fib N P P N N P N P P N N N P N P P P P P P P P P P N P P P N P P N N P N P P N N P N N N P P N P 







fnbA P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P 
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Table S 3 Correlation Matrix 
 Generation 













1.000000 0.033370 -0.160190 0.110662 0.233531 -0.091708 -0.075685 -0.211572 -0.190661 
Sig. (2-tailed)   0.825746 0.287579 0.464080 0.118293 0.544410 0.617139 0.158099 0.204362 





0.033370 1.000000 0.365156* -0.421845** -0.400432** 0.383605** 0.276966 0.485908** 0.519704** 
Sig. (2-tailed) 0.825746   0.012586 0.003500 0.005824 0.008497 0.062404 0.000618 0.000214 





-0.160190 0.365156* 1.000000 -0.327978* -0.332347* 0.457747** 0.194203 0.525008** 0.605797** 
Sig. (2-tailed) 0.287579 0.012586   0.026069 0.024032 0.001381 0.195924 0.000180 0.000008 





0.110662 -0.421845** -0.327978* 1.000000 0.823584** -0.187706 -0.248296 -0.595023** -0.427704** 
Sig. (2-tailed) 0.464080 0.003500 0.026069   0.000000 0.211596 0.096142 0.000013 0.003028 






0.233531 -0.400432** -0.332347* 0.823584** 1.000000 -0.165556 -0.260068 -0.481838** -0.433611** 
Sig. (2-tailed) 0.118293 0.005824 0.024032 0.000000   0.271521 0.080898 0.000698 0.002609 




-0.091708 0.383605** 0.457747** -0.187706 -0.165556 1.000000 0.322107* 0.357760* 0.583457** 
Sig. (2-tailed) 0.544410 0.008497 0.001381 0.211596 0.271521   0.029031 0.014644 0.000021 




-0.075685 0.276966 0.194203 -0.248296 -0.260068 0.322107* 1.000000 0.547826** 0.327536* 
Sig. (2-tailed) 0.617139 0.062404 0.195924 0.096142 0.080898 0.029031   0.000081 0.026282 








-0.211572 0.485908** 0.525008** -0.595023** -0.481838** 0.357760* 0.547826** 1.000000 0.685970** 
Sig. (2-tailed) 0.158099 0.000618 0.000180 0.000013 0.000698 0.014644 0.000081   0.000000 




-0.190661 0.519704** 0.605797** -0.427704** -0.433611** 0.583457** 0.327536* 0.685970** 1.000000 
Sig. (2-tailed) 0.204362 0.000214 0.000008 0.003028 0.002609 0.000021 0.026282 0.000000   
N 46 46 46 46 46 46 46 46 46 
            
*. Correlation is significant at the 0.05 level (2-tailed). 





6.1  Index of abbreviations 
°C degree Celsius 
µ growth rate 
µg microgram 
µm micrometre 
a.k.a. also known as 
ADAM10 A Disintegrin and Metalloprotease 10 
Agr accessory gene regulator 
AIP autoinducing peptide 
ALPL alkaline phosphatase  
AMP antimicrobial peptide 
ANOVA analysis of variance 
Bbp bone sialoprotein binding protein  
BHI brain heart infusion 
CC clonal complex 
CCL5 (a.k.a. RANTES) Chemokine (C-C motif) ligand 5 
cDNA complementary DNA 
CFU colony forming unit 
CHIPS chemotaxis inhibitory protein 
ClfA clumping factor A 
Cna collagen adhesin  
CoA staphylocoagulase 
DAMP damage-associated molecular pattern 
ddH2O double-distilled water 
DIC disseminated vascular coagulopathy 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPBS Dulbecco's phosphate-buffered saline 
dUTP desoxyuridine triphosphate 
e.g. exempli gratia, for example 
Eap (a.k.a. Map) extracellular adherence protein  
ECM extracellular matrix 
EDIN epidermal cell differentiation inhibitor 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
et al. et alii 
etc. et cetera 
FACS fluorescence-activated cell scanning 
FBS foetal bovine serum 
FITC fluorescein isothiocyanate 
FnBP fibronectin binding protein 
g generation time 
gDNA genomic DNA 
h hour(s) 
Hla  α-toxin, haemolysin α 
HlgACB γ-toxin 
HUVEC human umbilical vein endothelial cells 
i.a. inter alia  
IF interferon 
IL interleukin 
isd iron-regulated surface determinant 




Luk leukocidin  
MHC major-histocompatibility complex 
min minute(s) 
ml millilitre  
mM millimolar  
mm millimetre 
MOI multiplicity of infection 
MRSA methicillin-resistant S. aureus 
MSCRAMM microbial surface components recognizing adhesive matrix molecule 
MSSA methicillin-susceptible S. aureus 
NET neutrophil extracellular trap 
nm nanometre 
NO nitric oxide 
NOD nucleotide-binding oligomerization domain 
OD optical density 
p.i. post infection 
PAMP pathogen-associated molecular pattern 
PCR polymerase chain reaction 
pHOB primary human osteoblasts 
PRR pattern recognition receptor 
PSM Phenol soluble modulin 
PVL Panton-Valentin leukocidin 
qSOFA quick SOFA 
RANTES (a.k.a CCL5) regulated on activation, normal T cell expressed and secreted 
RNA ribonucleic acid 
RNA-seq RNA sequencing 
ROS reactive oxygen species 
rpm rounds per minute 
s second(s) 
s. see 
S. aureus Staphylococcus aureus 
S. carnosus Staphylococcus carnosus 
sak staphylokinase 
SCIN staphylococcal complement inhibitor 
SCV small colony variant 
SERAM secretable expanded repertoire adhesive molecules 
SigB sigma factor σB 
SOFA Sepsis-related Organ Failure Assessment 
Spa protein A 
SSL staphylococcal superantigen like protein 
TF tissue factor 
TLR toll-like receptor 
TNF-α tumour necrosis factor α 
TRAIL tumour necrosis factor-related apoptosis-inducing ligand 
TSST toxic shock syndrome toxin 
U unit(s)  
vs. versus 
vWbp von-Willebrand factor binding protein 
wt/vol weight / volume 
WTA wall teichoic acid  
xg gravitational acceleration 
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